Role of the Receptor for Advanced Glycation End Products (RAGE) and Its Ligands in Inflammatory Responses

Overview

Journal Biomolecules

Publisher MDPI

Specialties Biochemistry
Molecular Biology

Date 2025 Jan 8

PMID 39766257

Authors

Kaylen Cross

Stefan W Vetter

Yousuf Alam

Md Zahidul Hasan

Anupom Deb Nath

Estelle Leclerc

Affiliations

Soon will be listed here.

Abstract

Since its discovery in 1992, the receptor for advanced glycation end products (RAGE) has emerged as a key receptor in many pathological conditions, especially in inflammatory conditions. RAGE is expressed by most, if not all, immune cells and can be activated by many ligands. One characteristic of RAGE is that its ligands are structurally very diverse and belong to different classes of molecules, making RAGE a promiscuous receptor. Many of RAGE ligands are damaged associated molecular patterns (DAMPs) that are released by cells under inflammatory conditions. Although RAGE has been at the center of a lot of research in the past three decades, a clear understanding of the mechanisms of RAGE activation by its ligands is still missing. In this review, we summarize the current knowledge of the role of RAGE and its ligands in inflammation.

References

Sofroniew M, Vinters H . Astrocytes: biology and pathology. Acta Neuropathol. 2009; 119(1):7-35. PMC: 2799634. DOI: 10.1007/s00401-009-0619-8. View

Edgeworth J, Gorman M, Bennett R, Freemont P, Hogg N . Identification of p8,14 as a highly abundant heterodimeric calcium binding protein complex of myeloid cells. J Biol Chem. 1991; 266(12):7706-13. View

Nickel W, Rabouille C . Mechanisms of regulated unconventional protein secretion. Nat Rev Mol Cell Biol. 2009; 10(2):148-55. DOI: 10.1038/nrm2617. View

Turovskaya O, Foell D, Sinha P, Vogl T, Newlin R, Nayak J . RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis. 2008; 29(10):2035-43. PMC: 2556970. DOI: 10.1093/carcin/bgn188. View

Gajewska-Naryniecka A, Szwedowicz U, Lapinska Z, Rudno-Rudzinska J, Kielan W, Kulbacka J . Irreversible Electroporation in Pancreatic Cancer-An Evolving Experimental and Clinical Method. Int J Mol Sci. 2023; 24(5). PMC: 10002122. DOI: 10.3390/ijms24054381. View

Li J, Schmidt A . Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J Biol Chem. 1997; 272(26):16498-506. DOI: 10.1074/jbc.272.26.16498. View

Byun K, Yoo Y, Son M, Lee J, Jeong G, Park Y . Advanced glycation end-products produced systemically and by macrophages: A common contributor to inflammation and degenerative diseases. Pharmacol Ther. 2017; 177:44-55. DOI: 10.1016/j.pharmthera.2017.02.030. View

Sirois C, Jin T, Miller A, Bertheloot D, Nakamura H, Horvath G . RAGE is a nucleic acid receptor that promotes inflammatory responses to DNA. J Exp Med. 2013; 210(11):2447-63. PMC: 3804942. DOI: 10.1084/jem.20120201. View

Fritz G . RAGE: a single receptor fits multiple ligands. Trends Biochem Sci. 2011; 36(12):625-32. DOI: 10.1016/j.tibs.2011.08.008. View

10.

Ivanov S, Dragoi A, Wang X, Dallacosta C, Louten J, Musco G . A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood. 2007; 110(6):1970-81. PMC: 1976374. DOI: 10.1182/blood-2006-09-044776. View

11.

Vlassara H, Li Y, Imani F, Wojciechowicz D, Yang Z, Liu F . Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Mol Med. 1995; 1(6):634-46. PMC: 2229987. View

12.

Maillard-Lefebvre H, Boulanger E, Daroux M, Gaxatte C, Hudson B, Lambert M . Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases. Rheumatology (Oxford). 2009; 48(10):1190-6. DOI: 10.1093/rheumatology/kep199. View

13.

Shirasawa M, Fujiwara N, Hirabayashi S, Ohno H, Iida J, Makita K . Receptor for advanced glycation end-products is a marker of type I lung alveolar cells. Genes Cells. 2004; 9(2):165-74. DOI: 10.1111/j.1356-9597.2004.00712.x. View

14.

Yan S, Naka Y, Hudson B, Herold K, Yan S, Ramasamy R . The ligand/RAGE axis: lighting the fuse and igniting vascular stress. Curr Atheroscler Rep. 2006; 8(3):232-9. DOI: 10.1007/s11883-006-0078-9. View

15.

Hilmenyuk T, Bellinghausen I, Heydenreich B, Ilchmann A, Toda M, Grabbe S . Effects of glycation of the model food allergen ovalbumin on antigen uptake and presentation by human dendritic cells. Immunology. 2009; 129(3):437-45. PMC: 2826688. DOI: 10.1111/j.1365-2567.2009.03199.x. View

16.

Bresnick A, Weber D, Zimmer D . S100 proteins in cancer. Nat Rev Cancer. 2015; 15(2):96-109. PMC: 4369764. DOI: 10.1038/nrc3893. View

17.

Kalea A, Reiniger N, Yang H, Arriero M, Schmidt A, Hudson B . Alternative splicing of the murine receptor for advanced glycation end-products (RAGE) gene. FASEB J. 2009; 23(6):1766-74. PMC: 2698653. DOI: 10.1096/fj.08-117739. View

18.

Su C, Jia S, Ma Z, Zhang H, Wei L, Liu H . HMGB1 Promotes Lymphangiogenesis through the Activation of RAGE on M2 Macrophages in Laryngeal Squamous Cell Carcinoma. Dis Markers. 2022; 2022:4487435. PMC: 8916867. DOI: 10.1155/2022/4487435. View

19.

Messmer D, Yang H, Telusma G, Knoll F, Li J, Messmer B . High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J Immunol. 2004; 173(1):307-13. DOI: 10.4049/jimmunol.173.1.307. View

20.

Hudson B, Carter A, Harja E, Kalea A, Arriero M, Yang H . Identification, classification, and expression of RAGE gene splice variants. FASEB J. 2007; 22(5):1572-80. DOI: 10.1096/fj.07-9909com. View